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Background and Aim:Drug-induced liver injury (DILI) is a known compli-
cation of volatile anesthetic (VA) agents, and, despite being rare, DILI can
be serious. One mechanism of VA-DILI occurs via interleukin 4 (IL-4)-
driven upregulation of cytochrome P450-2E1, leading to the formation of
drug metabolites (haptens) that trigger IL-4-driven antigen-specific T cells
and autoantibodies. Our group has developed biomarkers for liver injury
and have examined this in patients before and after VA exposure. The aim
of this prospective study was to determine the early markers of VA-DILI.
Methods: We prospectively followed patients having a VA general anes-
thetic (sevoflurane and/or desflurane) and compared them with those who
received regional or total intravenous anesthesia. Exclusion criteria were
known liver disease or any episode of significant hypotension. Baseline data
on patient demographics and comorbidities were collected, and blood was
analyzed for liver biochemistry, macrophage activation markers (CD206,
CD163), and IgG1 and IgG4 antibodies to JHDN5 (the CYP2E1 epitope)
and trifluoroacetyl (TFA), the VA drug hapten. Follow-up blood samples
were taken 48 h postoperatively and compared with baseline results. DILI
was defined as an alanine aminotransferase (ALT) level greater than two
times the upper limit of normal (ULN) and post-review agreement by an ex-
pert panel, taking into account the pattern of liver function test result de-
rangement and intraoperative events.
Results: Of 229 patients recruited, 16 developed an ALT level> 2 × ULN.
Twelve were considered likely to have VA-DILI, including four with an
ALT rise >3 × ULN. There was a trend to associate VA-DILI with obesity
(RR, 2.98; P = 0.063); however, the association with dyslipidemia (RR,
1.47; P = 0.72), male sex (RR, 1.18; P = 0.76), history of atopy (RR,
1.16; P = 0.79), and heavy ethanol consumption (RR, 1.09; P = 0.89)
was not statistically significant. Prior VA exposure was not a risk factor
(RR, 0.89; P = 0.83). There was a rise in CD206 and decline in CD163
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from baseline in all patients. However, in the patients with VA-DILI, the
levels were significantly different from all other groups. TFA IgG1 and
IgG4 antibodies were elevated in the VA-DILI group when compared with
controls.
Conclusion: Recognizing that our results may be skewed by our cohort,
this work suggests the known immunological pathway mediated by IL-4
in response to an injury: rise in CD206 to stimulate an inflammatory re-
sponse, and decrease in CD163 to modulate the response. The increase in
TFA IgG1 and IgG4 antibodies in the VA-DILI group is consistent with
metabolism and the heightened immune response in those who develop
DILI. At this early juncture, JHDN5 IgG4 autoantibodies were not de-
tected. Ongoing work is looking at other DILI, and how these markers
can be used in DILI.
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